Trial Outcomes & Findings for A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT) (NCT NCT01618669)

NCT ID: NCT01618669

Last Updated: 2016-02-08

Results Overview

SPECT scans were reviewed in a blinded fashion by 3 independent expert readers using the 17-segment model for standardized myocardial segmentation. At rest and stress, each segment was scored on a 0 (normal) to 4 (absent contrast/radiotracer uptake) scale by each of the 3 blinded readers according to the amount of contrast or radiotracer the myocardium in the segment absorbed. If the stress score was ≥ 2 and the rest score was less than the stress score, the segment was counted as having a reversible defect. The number of segments with reversible defects was categorized as absence (0 - 1 reversible segments) or presence (≥ 2 defects reversible segments) of ischemia. Each reader was defined as having self-agreement based upon identical categorization of a given participant as absent or present for ischemia for both the initial and second stress visits. Majority agreement is if at least 2 out of the 3 blinded readers demonstrated self-agreement for a given participant.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

1147 participants

Primary outcome timeframe

Day 1 (rest scan and first stress scan) and Day 2 -15 (second stress scan)

Results posted on

2016-02-08

Participant Flow

This study was conducted at 49 sites in a total of 3 countries including the United States (44 sites), Argentina (4 sites) and Peru (1 site).

At Baseline, patients meeting all inclusion/exclusion criteria completed single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) while at rest. Participants then underwent a Bruce or modified Bruce exercise protocol; those unable to reach 85% maximum predicted heart rate and/or 5 metabolic equivalents were randomized.

Participant milestones

Participant milestones
Measure
Regadenoson After Peak Exercise
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT myocardial perfusion imaging (MPI). One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Overall Study
STARTED
578
569
Overall Study
Received Treatment
575
567
Overall Study
COMPLETED
544
546
Overall Study
NOT COMPLETED
34
23

Reasons for withdrawal

Reasons for withdrawal
Measure
Regadenoson After Peak Exercise
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT myocardial perfusion imaging (MPI). One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Overall Study
Lost to Follow-up
1
1
Overall Study
Randomized but Never Received Study Drug
3
2
Overall Study
Adverse Event
16
7
Overall Study
Protocol Violation
5
3
Overall Study
Withdrawal by Subject
9
9
Overall Study
Miscellaneous Reason
0
1

Baseline Characteristics

A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Regadenoson After Peak Exercise
n=575 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone
n=567 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Total
n=1142 Participants
Total of all reporting groups
Age, Continuous
61.9 years
STANDARD_DEVIATION 11.45 • n=99 Participants
61.9 years
STANDARD_DEVIATION 11.19 • n=107 Participants
61.9 years
STANDARD_DEVIATION 11.32 • n=206 Participants
Sex: Female, Male
Female
234 Participants
n=99 Participants
239 Participants
n=107 Participants
473 Participants
n=206 Participants
Sex: Female, Male
Male
341 Participants
n=99 Participants
328 Participants
n=107 Participants
669 Participants
n=206 Participants
Bruce Exercise Group
Standard Bruce Exercise
448 participants
n=99 Participants
442 participants
n=107 Participants
890 participants
n=206 Participants
Bruce Exercise Group
Modified Bruce Exercise
90 participants
n=99 Participants
93 participants
n=107 Participants
183 participants
n=206 Participants
Maximum Metabolic Equivalents Achieved
5.45 metabolic equivalents
STANDARD_DEVIATION 2.284 • n=99 Participants
5.37 metabolic equivalents
STANDARD_DEVIATION 2.331 • n=107 Participants
5.41 metabolic equivalents
STANDARD_DEVIATION 2.307 • n=206 Participants

PRIMARY outcome

Timeframe: Day 1 (rest scan and first stress scan) and Day 2 -15 (second stress scan)

Population: Full Analysis Set

SPECT scans were reviewed in a blinded fashion by 3 independent expert readers using the 17-segment model for standardized myocardial segmentation. At rest and stress, each segment was scored on a 0 (normal) to 4 (absent contrast/radiotracer uptake) scale by each of the 3 blinded readers according to the amount of contrast or radiotracer the myocardium in the segment absorbed. If the stress score was ≥ 2 and the rest score was less than the stress score, the segment was counted as having a reversible defect. The number of segments with reversible defects was categorized as absence (0 - 1 reversible segments) or presence (≥ 2 defects reversible segments) of ischemia. Each reader was defined as having self-agreement based upon identical categorization of a given participant as absent or present for ischemia for both the initial and second stress visits. Majority agreement is if at least 2 out of the 3 blinded readers demonstrated self-agreement for a given participant.

Outcome measures

Outcome measures
Measure
Regadenoson After Peak Exercise
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone
n=535 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 1
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 2
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
Proportion of Participants With Majority Reader Self-agreement in Ischemia Assessment Between First and Second Stress Scans
0.92 proportion of participants
Interval 0.89 to 0.94
0.95 proportion of participants
Interval 0.93 to 0.97

SECONDARY outcome

Timeframe: Within 1 hour for ECG events and up to 24 hours for adverse events after administration of regadenoson

Population: Safety analysis set (all randomized participants who received at least 1 dose of regadenoson study drug)

A clinically significant cardiac event is defined as: * Any of the following events found on the Holter electrocardiogram (ECG)/12-Lead ECG within 1 hour after regadenoson administration: * ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes, ventricular flutter), * ST-T depression (\> 2 mm), * ST-T elevation (≥1 mm), * Atrioventricular (AV) block (2:1 AV block, AV Mobitz I, AV Mobitz II, complete heart block) * sinus arrest \> 3 seconds in duration Or * a treatment-emergent adverse event (TEAE) per the Medical Dictionary for Regulatory Activities (MedDRA) Standardised MedDRA Queries (SMQ) (Narrow Scope) for myocardial infarction Or * a TEAE preferred term of angina unstable within 24 hours of regadenoson administration.

Outcome measures

Outcome measures
Measure
Regadenoson After Peak Exercise
n=575 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone
n=544 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 1
n=567 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 2
n=548 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Any Event
3.0 percentage of participants
0.9 percentage of participants
0.5 percentage of participants
0.4 percentage of participants
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Any TEAE per SMQ for Myocardial Infarction
0.3 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Acute Coronary Syndrome
0.2 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Any Holter/12-Lead ECG Abnormality
2.8 percentage of participants
0.9 percentage of participants
0.5 percentage of participants
0.4 percentage of participants
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Sustained Ventricular Tachycardia
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Ventricular Fibrillation or Ventricular Flutter
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Torsade de Pointes
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
ST-T Depression (≥ 2 mm)
2.3 percentage of participants
0.6 percentage of participants
0.4 percentage of participants
0.4 percentage of participants
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
ST-T Elevation (≥ 1 mm)
0.5 percentage of participants
0.4 percentage of participants
0.2 percentage of participants
0.0 percentage of participants
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
2:1 AV Block
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Mobitz I Second Degree AV Block
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Mobitz II Second Degree AV Block
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Complete Heart Block
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Pause > 3.0 seconds
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Myocardial Infarction
0.2 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
Percentage of Participants With Treatment-emergent Clinically Significant Cardiac Events
Adverse Event of Angina Unstable
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants
0.0 percentage of participants

SECONDARY outcome

Timeframe: Day 1 (stress MPI 1) and Day 2 -15 (stress MPI 2)

Population: Full Analysis Set

The number of segments with reversible defects was assessed by each of the 3 blinded independent expert readers. Based on the median count of the number of reversible defects across the 3 readers, categorized as absence (0 to 1 reversible segments) or presence (≥ 2 reversible defects) of ischemia, the proportion of participants with agreement in the presence and absence of ischemia between the first and second stress scans was calculated.

Outcome measures

Outcome measures
Measure
Regadenoson After Peak Exercise
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone
n=535 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 1
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 2
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
Proportion of Participants With Agreement in the Assessment of Absence or Presence of Ischemia Between First and Second Stress Scans
0.75 proportion of participants
Interval 0.68 to 0.83
0.77 proportion of participants
Interval 0.67 to 0.86

SECONDARY outcome

Timeframe: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)

Population: Full Analysis Set

The number of segments with reversible defects was assessed by each of the 3 blinded independent expert readers. Based on the median count of the number of reversible defects across the 3 readers, categorized as 0 to 1, 2 to 4, or ≥ 5 reversible segments, the proportion of participants with agreement in the three ischemia categories between the first and second stress scans was to be calculated. In the reported data, these proportions only include the 0-1 and 2-4 categories; the ≥ 5 category was not included because there were no participants in this category for the Regadenoson Alone group for the initial stress MPI.

Outcome measures

Outcome measures
Measure
Regadenoson After Peak Exercise
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone
n=535 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 1
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 2
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
Proportion of Participants With Agreement in the Assessment of Reversible Defects in 3 Categories of Ischemia Between First and Second Stress Scans
0.73 proportion of participants
Interval 0.69 to 0.77
0.75 proportion of participants
Interval 0.71 to 0.78

SECONDARY outcome

Timeframe: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)

Population: Full Analysis Set

The 17-segment model for standardized myocardial segmentation was used to analyze MPI scans. Each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed: * 0: normal perfusion * 1: slightly reduced contrast/radiotracer uptake * 2: moderately reduced contrast/radiotracer uptake * 3: severely reduced contrast/radiotracer uptake * 4: absent contrast/radiotracer uptake. The Summed Stress Score (SSS) was calculated as the sum of the stress scores across the 17 segments. The mean value (rounded to the nearest integer) across the 3 readers was computed and the SSS was categorized into 4 group categorical variables based on the score: 0 to 3, 4 to 7, 8 to 11, and ≥ 12. The proportion of participants with agreement in respect to these categories between the two stress scans was calculated.

Outcome measures

Outcome measures
Measure
Regadenoson After Peak Exercise
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone
n=535 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 1
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 2
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
Proportion of Participants With Agreement in the Summed Stress Score (SSS) Between First and Second Stress Scans
0.86 proportion of participants
0.84 proportion of participants

SECONDARY outcome

Timeframe: Day 1 (rest MPI and stress MPI 1) and Day 2 - 15 (stress MPI 2)

Population: Full Analysis Set

The 17-segment model for standardized myocardial segmentation was used to analyze MPI scans. At rest and stress, each segment was scored on a 0 to 4 scale according to the amount of contrast or radiotracer the myocardium in the segment absorbed: * 0: normal perfusion * 1: slightly reduced contrast/ uptake * 2: moderately reduced contrast/uptake * 3: severely reduced contrast/uptake * 4: absent contrast/uptake. SSS was calculated as the sum of the stress scores across the 17 segments and the Summed Rest Score (SRS) was calculated as the sum of the rest scores across the 17 segments. The Summed Difference Score (SDS) is the difference in the SSS and SRS (SSS - SRS). The mean value (rounded to the nearest integer) across the 3 readers was computed and the SDS was categorized into 3 categorical variables based on the score: 0 to 6, 7 to 13 and ≥ 14. The proportion of participants with agreement in respect to these categories between the two stress scans was calculated.

Outcome measures

Outcome measures
Measure
Regadenoson After Peak Exercise
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 1
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 2
n=535 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
REG Alone: MPI 2 SDS 7-13
n=535 Participants
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
REG Alone: MPI 2 SDS ≥ 14
n=535 Participants
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
Proportion of Participants With Agreement in the Summed Difference Score (SDS) Between First and Second Stress Scans
MPI 1 SDS 0-6
531 participants
4 participants
0 participants
527 participants
3 participants
0 participants
Proportion of Participants With Agreement in the Summed Difference Score (SDS) Between First and Second Stress Scans
MPI 1 SDS 7-13
0 participants
3 participants
0 participants
2 participants
3 participants
0 participants
Proportion of Participants With Agreement in the Summed Difference Score (SDS) Between First and Second Stress Scans
MPI 1 SDS ≥ 14
0 participants
0 participants
0 participants
0 participants
0 participants
0 participants

SECONDARY outcome

Timeframe: Day 1 (stress MPI 1) and Day 2-15 (stress MPI 2)

Population: Full Analysis Set

Each reader evaluated the initial stress SPECT MPI scan compared to the participant's second stress SPECT MPI scan (blinded at time of the evaluation) for whether there was Less (-1), the Same (0) or More (1) reversible perfusion defects. The median assessment of the 3 blinded readers was used to summarize the number of participants in each category.

Outcome measures

Outcome measures
Measure
Regadenoson After Peak Exercise
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone
n=535 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 1
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 2
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
Participants With Less, the Same, or More Reversible Perfusion Defects Shown by the First Stress Scan When Compared to the Second Stress Scan
Less Reversible Perfusion Defects
57 participants
49 participants
Participants With Less, the Same, or More Reversible Perfusion Defects Shown by the First Stress Scan When Compared to the Second Stress Scan
Same Number of Reversible Perfusion Defects
441 participants
459 participants
Participants With Less, the Same, or More Reversible Perfusion Defects Shown by the First Stress Scan When Compared to the Second Stress Scan
More Reversible Perfusion Defects
40 participants
27 participants

SECONDARY outcome

Timeframe: Day 1 (rest MPI and stress MPI 1) and Day 2 - 15 (stress MPI 2)

Population: Full Analysis Set

The image quality for each scan was rated by each independent reader as 1 = Poor, 2 = Fair, 3 = Good, 4 = Excellent. Based on the median rating of overall image quality across the three readers, the number of participants with each rating is reported for each scan.

Outcome measures

Outcome measures
Measure
Regadenoson After Peak Exercise
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone
n=535 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 1
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 2
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
Overall Assessment of Image Quality
Stress MPI 2: Fair
43 participants
37 participants
Overall Assessment of Image Quality
Stress MPI 2: Poor
0 participants
0 participants
Overall Assessment of Image Quality
Rest MPI: Excellent
140 participants
157 participants
Overall Assessment of Image Quality
Rest MPI: Good
307 participants
308 participants
Overall Assessment of Image Quality
Rest MPI: Fair
91 participants
70 participants
Overall Assessment of Image Quality
Rest MPI: Poor
0 participants
0 participants
Overall Assessment of Image Quality
Stress MPI 1: Excellent
224 participants
211 participants
Overall Assessment of Image Quality
Stress MPI 1: Good
287 participants
291 participants
Overall Assessment of Image Quality
Stress MPI 1: Fair
27 participants
33 participants
Overall Assessment of Image Quality
Stress MPI 1: Poor
0 participants
0 participants
Overall Assessment of Image Quality
Stress MPI 2: Excellent
192 participants
205 participants
Overall Assessment of Image Quality
Stress MPI 2: Good
303 participants
293 participants

SECONDARY outcome

Timeframe: Day 1 (stress MPI 1) and Day 2 - 15 (stress MPI 2)

Population: Full analysis set participants who have planar images available for each scan

Image quality was assessed through radiotracer uptake in the heart (target organ) compared to liver, gut and combined liver plus gut (background interference).

Outcome measures

Outcome measures
Measure
Regadenoson After Peak Exercise
n=514 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone
n=525 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 1
n=518 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 2
n=523 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
Target to Background Radiotracer Uptake Ratios From the First and Second Stress Scans
Heart-to-Gut
1.12 ratio
Standard Deviation 0.436
0.99 ratio
Standard Deviation 0.399
1.05 ratio
Standard Deviation 0.428
0.99 ratio
Standard Deviation 0.387
Target to Background Radiotracer Uptake Ratios From the First and Second Stress Scans
Heart-to-Liver
1.05 ratio
Standard Deviation 0.399
0.94 ratio
Standard Deviation 0.373
0.96 ratio
Standard Deviation 0.365
0.95 ratio
Standard Deviation 0.362
Target to Background Radiotracer Uptake Ratios From the First and Second Stress Scans
Heart-to-(Liver/Gut)
1.02 ratio
Standard Deviation 0.296
0.90 ratio
Standard Deviation 0.260
0.94 ratio
Standard Deviation 0.274
0.91 ratio
Standard Deviation 0.259

SECONDARY outcome

Timeframe: Day 1 (stress MPI 1) and Day 2 -15 (stress MPI 2)

Population: Full Analysis Set

Each reader assessed the sub-diaphragmatic radiotracer interference with cardiac image quality using a 4-point scale of 0 = none, 1 = slight, 2 = moderate or 3 = severe for each stress SPECT MPI. The median rating across the 3 readers was used to summarize the percentage of scans with interference.

Outcome measures

Outcome measures
Measure
Regadenoson After Peak Exercise
n=284 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone
n=284 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 1
n=270 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 2
n=270 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
Percentage of Scans With Subdiaphragmatic Interference
Slight
71.8 percentage of stress MPI scans
63.7 percentage of stress MPI scans
68.1 percentage of stress MPI scans
67.4 percentage of stress MPI scans
Percentage of Scans With Subdiaphragmatic Interference
None
0.4 percentage of stress MPI scans
0.0 percentage of stress MPI scans
0.0 percentage of stress MPI scans
0.0 percentage of stress MPI scans
Percentage of Scans With Subdiaphragmatic Interference
Moderate
27.5 percentage of stress MPI scans
36.3 percentage of stress MPI scans
31.5 percentage of stress MPI scans
32.6 percentage of stress MPI scans
Percentage of Scans With Subdiaphragmatic Interference
Severe
0.4 percentage of stress MPI scans
0.0 percentage of stress MPI scans
0.4 percentage of stress MPI scans
0.0 percentage of stress MPI scans

SECONDARY outcome

Timeframe: Day 1 (stress MPI 1) and Day - 15 (stress MPI 2)

Population: Full Analysis Set

The number of cardiac segments obscured by the sub-diaphragmatic activity by group by stress SPECT MPI scan and by reader is reported.

Outcome measures

Outcome measures
Measure
Regadenoson After Peak Exercise
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone
n=538 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 1
n=535 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 2
n=535 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 3
0.0 percentage of segments
0.0 percentage of segments
0.2 percentage of segments
0.6 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 4
34.4 percentage of segments
35.1 percentage of segments
32.5 percentage of segments
32.5 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 6
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 8
0.0 percentage of segments
0.2 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 9
0.0 percentage of segments
0.0 percentage of segments
0.4 percentage of segments
0.4 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 12
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 13
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 14
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 17
0.4 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 3
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 4
14.1 percentage of segments
16.7 percentage of segments
17.9 percentage of segments
17.2 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 9
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 10
16.0 percentage of segments
17.8 percentage of segments
18.5 percentage of segments
18.9 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 1
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 2
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 3
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 4
33.6 percentage of segments
37.2 percentage of segments
34.2 percentage of segments
37.4 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 5
9.7 percentage of segments
8.4 percentage of segments
7.9 percentage of segments
7.7 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 6
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 7
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 8
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 9
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 10
31.6 percentage of segments
35.5 percentage of segments
32.3 percentage of segments
36.3 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 11
9.5 percentage of segments
8.2 percentage of segments
7.5 percentage of segments
7.5 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 12
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 13
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 14
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 15
1.7 percentage of segments
0.9 percentage of segments
2.4 percentage of segments
2.1 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 16
0.0 percentage of segments
0.0 percentage of segments
0.2 percentage of segments
0.2 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 1: Segment 17
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 1
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 2
0.0 percentage of segments
0.0 percentage of segments
0.2 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 5
1.1 percentage of segments
0.4 percentage of segments
0.7 percentage of segments
0.7 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 7
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 10
12.6 percentage of segments
11.9 percentage of segments
13.8 percentage of segments
13.1 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 11
0.0 percentage of segments
0.2 percentage of segments
0.6 percentage of segments
0.2 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 15
9.1 percentage of segments
8.7 percentage of segments
10.5 percentage of segments
9.5 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 2: Segment 16
0.0 percentage of segments
0.2 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 1
0.0 percentage of segments
0.2 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 2
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 5
0.6 percentage of segments
0.4 percentage of segments
0.7 percentage of segments
0.2 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 6
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 7
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 8
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 11
0.7 percentage of segments
0.2 percentage of segments
0.6 percentage of segments
0.2 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 12
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 13
0.2 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 14
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
0.0 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 15
13.9 percentage of segments
13.8 percentage of segments
13.1 percentage of segments
14.6 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 16
0.4 percentage of segments
0.7 percentage of segments
0.4 percentage of segments
0.2 percentage of segments
Percentage of Cardiac Segments Obscured by Subdiaphragmatic Activity
Reader 3: Segment 17
0.9 percentage of segments
0.9 percentage of segments
0.7 percentage of segments
0.6 percentage of segments

SECONDARY outcome

Timeframe: Up to 24 hours after study drug administration for each stress MPI (Day 1 and Day 2-15)

Population: Safety Analysis Set.

An adverse event is considered "serious" if, in the view of either the investigator or sponsor, it results in any of the following outcomes: * Results in death, * Is life threatening, * Results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, * Results in congenital anomaly, or birth defect, * Requires inpatient hospitalization or leads to prolongation of hospitalization * Other medically important events. Relationship to study drug was assessed by the investigator.

Outcome measures

Outcome measures
Measure
Regadenoson After Peak Exercise
n=575 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone
n=544 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 1
n=567 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 2
n=548 Participants
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
REG Alone: MPI 2 SDS 7-13
Participants in the Regadenoson (REG) Alone group who had an SDS from 7 to 13 on their second stress scan.
REG Alone: MPI 2 SDS ≥ 14
Participants in the Regadenoson (REG) Alone group who had an SDS ≥ 14 on their second stress scan.
Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson
Drug-related adverse event
291 participants
298 participants
319 participants
308 participants
Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson
Any adverse event
302 participants
317 participants
329 participants
323 participants
Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson
Deaths
0 participants
0 participants
0 participants
0 participants
Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson
Serious adverse events
5 participants
2 participants
1 participants
1 participants
Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson
Drug-related serious adverse events
2 participants
0 participants
0 participants
0 participants
Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson
Adverse events leading to discontinuation
13 participants
0 participants
5 participants
1 participants
Number of Participants With Adverse Events Within 24 Hours After Administration of Regadenoson
Drug-related AEs leading to discontinuation
9 participants
0 participants
5 participants
0 participants

Adverse Events

Regadenoson After Peak Exercise: MPI 1

Serious events: 5 serious events
Other events: 277 other events
Deaths: 0 deaths

Regadenoson After Peak Exercise: MPI 2

Serious events: 2 serious events
Other events: 274 other events
Deaths: 0 deaths

Regadenoson Alone: MPI 1

Serious events: 1 serious events
Other events: 307 other events
Deaths: 0 deaths

Regadenoson Alone: MPI 2

Serious events: 1 serious events
Other events: 290 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Regadenoson After Peak Exercise: MPI 1
n=575 participants at risk
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson After Peak Exercise: MPI 2
n=544 participants at risk
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 1
n=567 participants at risk
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 2
n=548 participants at risk
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Cardiac disorders
Acute coronary syndrome
0.17%
1/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
Cardiac disorders
Cardiac failure congestive
0.00%
0/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.18%
1/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
Cardiac disorders
Myocardial infarction
0.17%
1/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
Cardiac disorders
Myocardial ischaemia
0.17%
1/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.18%
1/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
Eye disorders
Vision blurred
0.17%
1/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
Gastrointestinal disorders
Pancreatitis
0.00%
0/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.18%
1/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
Investigations
Anticoagulation drug level below therapeutic
0.00%
0/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.18%
1/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
Investigations
Hepatic enzyme abnormal
0.17%
1/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
Nervous system disorders
Dizziness
0.17%
1/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
Nervous system disorders
Speech disorder
0.17%
1/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
Nervous system disorders
Syncope
0.17%
1/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
0.00%
0/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.

Other adverse events

Other adverse events
Measure
Regadenoson After Peak Exercise: MPI 1
n=575 participants at risk
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson After Peak Exercise: MPI 2
n=544 participants at risk
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 1
n=567 participants at risk
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Regadenoson Alone: MPI 2
n=548 participants at risk
On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, (1 hour after exercise recovery) and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
Gastrointestinal disorders
Abdominal pain upper
5.4%
31/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
6.4%
35/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
6.2%
35/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
6.2%
34/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
Gastrointestinal disorders
Nausea
7.5%
43/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
8.1%
44/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
7.9%
45/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
7.5%
41/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
General disorders
Chest discomfort
6.4%
37/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
6.1%
33/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
9.5%
54/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
7.8%
43/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
Nervous system disorders
Dizziness
18.4%
106/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
13.8%
75/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
15.7%
89/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
14.8%
81/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
Nervous system disorders
Headache
14.8%
85/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
19.9%
108/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
24.2%
137/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
21.5%
118/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
Respiratory, thoracic and mediastinal disorders
Dyspnoea
24.5%
141/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
23.0%
125/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
28.4%
161/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
27.7%
152/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
Vascular disorders
Flushing
8.2%
47/575 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
14.3%
78/544 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
13.9%
79/567 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.
12.6%
69/548 • From the time of administration of regadenoson to within 24 hours of administration of regadenoson for each stress MPI.

Additional Information

Senior Medical Director, Medical Affairs

Astellas Pharma Global Development, Inc. (APGD)

Results disclosure agreements

  • Principal investigator is a sponsor employee Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data or 18 months after data-lock, whichever is first. Sponsor must receive a site's manuscript at least 45 days prior to publication for review and comment. Sponsor may delay the publication for up to 60 days to seek patent protection.
  • Publication restrictions are in place

Restriction type: OTHER